Jerusalem-based Teva Pharmaceutical Industries has entered into an agreement to purchase a 51% equity share of Immuneering, a Cambridge, Mass.-based genomic-analysis company. Immuneering uses advanced proprietary techniques to identify hidden signals and biological insights across an array of genetic, genomic, and proteomic data that can direct research for enhanced discovery, development and clinical success.

Teva and Immuneering have worked together over the past several years to unlock genetic biomarkers, therapy-specific gene expression signatures and characterizing non-biological complex drugs (NBCDs). Teva’s majority holding in Immuneering provides right of first refusal in projects relating to the company’s stated objective of developing, personalizing and improving treatment of disorders of the central nervous system (CNS).